β-cell-selective inhibition of DNA damage response signaling by nitric oxide is associated with an attenuation in

Chay Teng Yeo1, Erin M Kropp1, Polly A Hansen1

  • 1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Insights

Nitric oxide (NO) selectively inhibits DNA damage response (DDR) signaling in pancreatic beta-cells by impairing mitochondrial metabolism. This metabolic inflexibility causes beta-cells to enter a state of suspended animation, preserving them until NO is cleared.

Area of Science:

  • Cellular metabolism
  • DNA damage response
  • Pancreatic beta-cell biology

Background:

  • Nitric oxide (NO) has a complex role in DNA damage response (DDR) signaling within pancreatic beta-cells.
  • At high concentrations, NO inhibits DDR signaling and apoptosis selectively in beta-cells.
  • This inhibition is linked to reduced mitochondrial oxidative metabolism, leading to decreased ATP and NAD+ levels.

Purpose of the Study:

  • To investigate the metabolic changes in beta-cells and non-beta-cells under conditions of NO exposure or mitochondrial inhibition.
  • To elucidate the mechanisms behind beta-cell-selective DDR inhibition by NO.

Main Methods:

  • Utilized multiple analytical approaches to measure intermediary metabolites.
  • Treated beta-cells and non-beta-cells with nitric oxide (NO) or rotenone (complex I inhibitor).
  • Assessed changes in ATP, NAD+, glycolytic intermediates, tricarboxylic acid cycle intermediates, and NADPH.

Main Results:

  • NO and rotenone significantly decreased ATP, NAD+, glycolytic and TCA cycle intermediates, and NADPH in beta-cells.
  • Mitochondrial oxidation inhibitors reduced glucose uptake in a beta-cell-selective manner.
  • Observed a significant decrease in ATP below the Km for glucokinase, impacting glucose uptake.

Conclusions:

  • Beta-cell-selective inhibition of DDR by NO is associated with metabolic shutdown.
  • Reduced ATP levels below glucokinase's Km impair glucose uptake and lead to a beta-cell 'suspended animation' state.
  • This metabolic inertness protects beta-cells until NO is removed and normal function can resume.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
252
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
203
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
224
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
380